Clinerion rolls out recruitment services to countries in EEMEA
Clinerion Ltd. is a Basel, Switzerland-based software firm that provides a patient recruitment solution (PRS) for pharma and academic run trials.
The firm’s newly appointed Head of EEMEA Region, Bariş Erdoğan, is leading the new geographic expansion, based on the increased demand for data connectivity between clinical centers in these regions.
For example, there are only two open drug studies in Bahrain, and just two clinical studies have been registered in Yemen – ever.
Clinerion therefore uses a proprietary Big Data analytics technology to implement real-time data from e-health records from participating hospitals in each of its regions to aid trial recruitment.
Formerly Clinerion’s Country Head for Turkey, Erdoğan was responsible for overseeing and implementing more than 400 million case files for the firm’s PRS catchment area in Turkey.
“Now, hospitals in the EEMEA region have the opportunity to take a share of the global market for clinical trials,” said Erdoğan.
Countries to be covered in Clinerion’s service include: Greece, Poland, Czech Republic (‘Czechia’), Hungary, Romania, Croatia, Bulgaria, Slovakia, Slovenia, Serbia, Bosnia, Macedonia, Georgia, Iran, Saudi Arabia, Jordan, Lebanon, the United Arab Emirates, Azerbaijan, Israel, Egypt, South Africa, Algeria, and Tunisia.
As the global markets expand and become more versatile, Clinerion claims the technology will complement the listed countries’ already “high level of medical care infrastructure”.
“Clinerion offers [clinical centers in these hospitals] an effective way to come to the attention of trial sponsors and bring new studies to their countries,” Erdoğan added.
EU and US market saturation
In January, Clinerion added the Brazilian iHealth Group to its PRS in order roll out the service in South America, and in February, partnered with ASUS Life to permit use of its PRS in hospitals in Taiwan.
Ulf Claesson, CEO of Clinerion, also told Outsourcing-Pharma it has plans to extend its Asia trail to include Korea, China, Japan, and Singapore.
“The US and Europe currently perform the majority of trials run, but these markets are almost saturated. Newer markets like the BRIC [Brazil, Russia, India and China] are developing,” said Erdoğan.
This is particularly so for the Asian CRO market, which is projected to reach $57Bn by 2020.